Briotech Announces Multi-Million-Dollar Investment from Decathlon Capital as HOCI Disinfectant Demand Soars


Sep 15, 2020

Briotech, an innovator in the global manufacturing of a pure, authentic, stabilized form of Hypochlorous Acid (HOCI) products, including sanitizers, disinfectants, cleansers, skin care solutions and dental care products, has announced a multi-million-dollar investment by Decathlon Capital Partners.

The investment comes as Briotech ramps up production to meet surging global demand for its sanitizers and disinfectant due to the COVID-19 pandemic. Briotech is also in a product development cycle and will release several new disinfectant product solutions to the marketplace in the U.S. and abroad, meeting both short-term and long-term demand for a safe, pure and healthy solution to disinfection worldwide.

HOCI, also known as Hypochlorous Acid, is naturally produced by the human body’s disease-fighting white blood cells. Briotech’s patent-pending systems produce proven and pure HOCI products that are chemically indistinguishable from the HOCI produced inside the human body. The products include pure and stable forms of sanitizer, disinfectant, and cleanser that contain 0% Hypochlorite (Bleach), 0% Alcohol, 0% Ammonia and other harmful contaminants, additives, and buffers. The results are an effective pathogen-killing product, a surface cleanser, and skin care solutions that are remarkably efficient.

“Briotech’s pioneering form of HOCI is a breakthrough in public health that is fighting disease and infection around the globe through natural, pure and contaminant-free disinfection,” said Dan Terry, founder, and executive chairman of Briotech. “Decathlon Capital’s investment will bring more of this powerful product to market during a particularly critical moment in public health.”

Decathlon Capital’s investment will fund additional manufacturing capacity, continued R&D and product line expansions. Briotech manufactures its products at its facilities in Woodinville, Wash, and Waukegan, IL allowing the company to closely control the company’s supply chain and production quality. The company has a wide range of products for topical skin applications, dental use, cleaning, and sanitization and disinfection of offices and public spaces.

“As Briotech scales to meet global demand, partners like Decathlon Capital are key in our mission to make the world safer, healthier and more resilient against COVID-19 and the many other pathogens and bacteria that effect global public health,” said Rick Lockett, CEO of Briotech.

Briotech was an ideal fit for Decathlon Capital’s revenue-based financing model because of its strong revenue and powerful growth potential, said John Borchers, managing partner of the Palo Alto, Calif.-based financing firm.

“Briotech’s position in a high-growth market and key innovations in public health made the company a perfect candidate for Decathlon Capital’s revenue-based financing support,” said Borchers.

Decathlon Capital’s multi-million-dollar investment will be paid back through Briotech’s future revenue. No equity or ownership was transacted as a result of the investment.

No statements contained in this press release are meant to imply that Briotech HOCl is a treatment for COVID-19 or that the use of Briotech HOCl would prevent the contracting of that or any other disease. Briotech HOCl is not approved by the FDA to treat COVID-19 or any other disease at this time. There is no generally accepted treatment for COVID-19.

About Briotech
Briotech is a leading manufacturer of HOCI-based disinfectants and sanitizers, including a wide range of industry-specific electrochemically engineered solutions that mimic the HOCl produced inside the human body. The company’s products set the gold standard for efficacy and have been proven pure and stable through laboratory-tested review. Through Briotech’s achievements, for the first time in 130 years, HOCl can be produced at large scale without ill-defined or unknown contaminants, additives, buffers, or preservatives. Briotech’s product line includes a wide range of topical skin products, sanitizers, and office/public space disinfectant solutions. Learn more at

About Decathlon Capital Partners
Decathlon Capital Partners provides growth capital for companies seeking alternatives to traditional equity investment. Through the use of highly customized revenue-based financing solutions, Decathlon provides long-term growth capital without the dilution, loss of control and operational overhead that often comes with equity-based funding. With offices in Palo Alto and Park City, Decathlon is the largest revenue-based funding investor in the U.S. and is active across a wide range of sectors. Learn more at